Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Drug

Huadong Medicine’s Elahere Receives Approval for FRα Positive Cancer Treatment in China

Fineline Cube Jul 12, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced receiving approval to introduce Elahere (mirvetuximab...

Company Deals

WuXi Biologics Proposes Spin-Off and Listing of WuXi XDC on Hong Kong Stock Exchange

Fineline Cube Jul 11, 2023

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced the...

Company Drug

Jiangxi Jemincare Group Launches Omalizumab Biosimilar CMAB007 in China for Asthma and Dermatology

Fineline Cube Jul 11, 2023

Jiangxi Jemincare Group has overseen the official launch and first prescription of its omalizumab biosimilar,...

Company Deals

Zhejiang Doer Biologics Partners with BioNTech for Global Development of Innovative Biological Drugs

Fineline Cube Jul 11, 2023

Zhejiang Doer Biologics Co., Ltd, a China-based clinical-stage biopharmaceutical company, has announced a significant licensing...

Company Drug

C4 Therapeutics’ CFT8919 Earns FDA Approval for Clinical Trials Targeting EGFR L858R Mutations

Fineline Cube Jul 11, 2023

US-based C4 Therapeutics Inc., (NASDAQ: CCCC) has announced receiving clinical trial approval from the US...

Policy / Regulatory

NHSA’s 2022 Report: BMI Fund Income Rises 7.6%, Outgoing Expenditure Increases 2.3%

Fineline Cube Jul 11, 2023

The National Healthcare Security Administration (NHSA) has released its annual statistical report for 2022, detailing...

Company Drug

Zai Lab’s Vyvgart Receives NMPA Review for Subcutaneous Injection Form in gMG Treatment

Fineline Cube Jul 11, 2023

China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced that the National Medical Products...

Company Medical Device

Sino Medical Sciences Receives Approval for Next-Generation Drug-Eluting Stent in Indonesia

Fineline Cube Jul 11, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced receiving market approval for its...

Policy / Regulatory

Shanghai’s SMPA Initiates Volume-Based Procurement for National VBP Drugs in Alliance Region

Fineline Cube Jul 11, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification indicating the commencement of follow-up...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for HRS-9815 Radiodiagnostic Drug Clinical Study

Fineline Cube Jul 11, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval...

Company Deals

Everest Medicines and Sinopharm Group Ink MoU to Enhance Distribution and Collaboration

Fineline Cube Jul 11, 2023

China-based Everest Medicines (HKG: 1952) has announced the signing of a memorandum of understanding (MoU)...

Company Deals

BeiGene Secures Exclusive Licensing Deal with Duality Biotherapeutics for Novel Drug Development

Fineline Cube Jul 11, 2023

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced an exclusive option and licensing...

Company Deals

Bayer and Peking University Enter Fourth Phase of Partnership to Advance Drug Discovery

Fineline Cube Jul 11, 2023

Germany-based pharmaceutical giant Bayer (ETR: BAYN) has entered its fourth phase of partnership with the...

Company Drug

Transcenta Holding Ltd Secures Global Clinical Trial Approvals for Osemitamab in Gastric Cancer

Fineline Cube Jul 11, 2023

China-based Transcenta Holding Ltd has reported receiving clinical trial approvals from China’s Center for Drug...

Company

Pentax Medical to Establish Endoscope Manufacturing and R&D Site in Shanghai

Fineline Cube Jul 11, 2023

Japan-based Pentax Medical, a division of the Hoya Group specializing in endoscopic products, has announced...

Company Deals

Sinopep-Allsino Bio Pharmaceutical Cuts Fundraising Target to RMB434 Million via Convertible Bonds”

Fineline Cube Jul 10, 2023

Jiangsu-based Contract Development and Manufacturing Organization (CDMO) Sinopep-Allsino Biopharmaceutical Co., Ltd has revised its proposal...

Company Drug

Shanghai BDgene Technology Receives US FDA Approval for HSV-1 Stromal Keratitis Gene Therapy

Fineline Cube Jul 10, 2023

Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced receiving approval from the US...

Company Medical Device

Jenscare Scientific’s LuX-Valve Plus Accepted for US FDA Review in IDE Process

Fineline Cube Jul 10, 2023

Ningbo-based structural heart disease intervention device manufacturer, Jenscare Scientific Co., Ltd (HKG: 9877), has announced...

Company Medical Device

Broncus Medical Inc. Launches First Regulatory Clinical Study for Targeted Lung Denervation System

Fineline Cube Jul 10, 2023

China-based Broncus Medical Inc., (HKG: 2216), a provider of precision intervention solutions focused on lung...

Company Deals Digital

Hainan Boao Lecheng Partners with Medlive for Medical Tourism and Online Doctor Education

Fineline Cube Jul 10, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a strategic partnership...

Posts pagination

1 … 558 559 560 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.